Evidence map›Paper›PMID 38194233›Full record

ArticleJAMA network open2024

Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer.

Sheetal Kircher, Fenghai Duan, Na An, Ilanan F Gareen, JoRean D Sicks, Gelareh Sadigh, Jennifer M Suga, Heather Kehn, Paul T Mehan, Rajesh Bajaj and 7 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
28.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Long-term quality of life, financial toxicity, and decision regret following therapeutic and prophylactic gastrectomy for cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Sheetal KircherRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
Fenghai DuanDepartment of Biostatistics, Brown University School of Public Health, Providence, Rhode Island.
Na AnCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Ilanan F GareenCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
JoRean D SicksCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Gelareh SadighUniversity of California School of Medicine, Irvine.
Jennifer M SugaKaiser Permanente NCI Community Oncology Research Program and NCORP, Vallejo, California.
Heather KehnMetro-Minnesota Community Oncology Research Consortium, St Louis Park.
Paul T MehanMissouri Baptist Hospital NCORP, Saint Louis.
Rajesh BajajCarolina Health Care and NCORP, Florence, South Carolina.
David S HansonMary Bird Perkins Cancer Center, Baton Rouge, Louisiana.
Samir M DaliaMercy Hospital, Joplin, Missouri.
Jared D AcobaUniversity of Hawaii Cancer Center, Honolulu.
Demet Gokalp YasarMarshfield Clinic, Minocqua, Wisconsin.
Elyse R ParkMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Lynne I WagnerWake Forest University Health Sciences, Winston-Salem, North Carolina.
Ruth C CarlosUniversity of Michigan Comprehensive Cancer Center, Ann Arbor.
Brown University · USBaptist Hospital · USKaiser Permanente Vallejo Medical Center · USMarshfield Clinic · USMary Bird Perkins Cancer Center · USMassachusetts General Hospital · USMercy Hospital · USMetro-Minnesota Community Oncology Research Consortium · USNorthwestern University · USUniversity of California, Irvine · USUniversity of Hawaii System · USUniversity of Michigan · USWake Forest University · US

Funding

ECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Kaiser Permanente NCI National Community Oncology Research Program, NCORPUG1CA189821 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI Jennifer Marie Suga · 2014 to 2026
$44.4M
Metro-Minnesota Community Oncology Research Consortium (MMCORC)UG1CA189863 · NCI · PARK NICOLLET INSTITUTE · PI JOLEEN M HUBBARD, Yan Ji · 2014 to 2026
$43.2M
Heartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
Wisconsin NCI Community Oncology Research Program (WiNCORP)UG1CA189956 · NCI · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI ADEDAYO A ONITILO, Kurt Oettel · 2014 to 2026
$32.3M
Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)UG1CA189854 · NCI · LSU HEALTH SCIENCES CENTER · PI AUGUSTO C. OCHOA · 2014 to 2026
$27.1M
The Hawaii NCORPUG1CA189804 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Jared Acoba, Jeffrey Lee Berenberg · 2014 to 2026
$15.7M
NCI NIH HHS P30 CA062203NCI NIH HHS UG1 CA189804NCI NIH HHS UG1 CA189821NCI NIH HHS UG1 CA189822NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA189828NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189854NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189862NCI NIH HHS UG1 CA189863NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA189956NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233160NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233320
6 · The paper itself

Abstract

Importance: The longitudinal experience of patients is critical to the development of interventions to identify and reduce financial hardship. Objective: To evaluate financial hardship over 12 months in patients with newly diagnosed colorectal cancer (CRC) undergoing curative-intent therapy. Design, Setting, and Participants: This prospective, longitudinal cohort study was conducted between May 2018 and July 2020, with time points over 12 months. Participants included patients at National Cance Institute Community Oncology Research Program sites. Eligibility criteria included age at least 18 years, newly diagnosed stage I to III CRC, not started chemotherapy and/or radiation, treated with curative intent, and able to speak English. Data were analyzed from December 2022 through April 2023. Main Outcomes and Measures: The primary end point was financial hardship, measured using the Comprehensive Score for Financial Toxicity (COST), which assesses the psychological domain of financial hardship (range, 0-44; higher score indicates better financial well-being). Participants completed 30-minute surveys (online or paper) at baseline and 3, 6, and 12 months. Results: A total of 450 participants (mean [SD] age, 61.0 [12.0] years; 240 [53.3%] male) completed the baseline survey; 33 participants (7.3%) were Black and 379 participants (84.2%) were White, and 14 participants (3.1%) identified as Hispanic or Latino and 424 participants (94.2%) identified as neither Hispanic nor Latino. There were 192 participants (42.7%) with an annual household income of $60 000 or greater. There was an improvement in financial hardship from diagnosis to 12 months of 0.3 (95% CI, 0.2 to 0.3) points per month (P < .001). Patients with better quality of life and greater self-efficacy had less financial toxicity. Each 1-unit increase in Functional Assessment of Cancer Therapy-General (rapid version) score was associated with an increase of 0.7 (95% CI, 0.5 to 0.9) points in COST score (P < .001); each 1-unit increase in self-efficacy associated with an increase of 0.6 (95% CI, 0.2 to 1.0) points in COST score (P = .006). Patients who lived in areas with lower neighborhood socioeconomic status had greater financial toxicity. Neighborhood deprivation index was associated with a decrease of 0.3 (95% CI, -0.5 to -0.1) points in COST score (P = .009). Conclusions and Relevance: These findings suggest that interventions for financial toxicity in cancer care should focus on counseling to improve self-efficacy and mitigate financial worry and screening for these interventions should include patients at higher risk of financial burden.

Indexed as

Colorectal NeoplasmsRectal NeoplasmsFemaleFinancial StressHumansLongitudinal StudiesMaleMiddle AgedPatient Reported Outcome MeasuresProspective StudiesQuality of Life

Identifiers

PMID38194233
PMCPMC10777253
OpenAlexW4390769615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.